Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;34(3):424-426.
doi: 10.1038/s41433-019-0582-0. Epub 2019 Sep 16.

Brolucizumab: is extended VEGF suppression on the horizon?

Ashish Sharma  1 , Nilesh Kumar  2 , Baruch D Kuppermann  3 , Anat Loewenstein  4 , Francesco Bandello  5
Affiliations

Brolucizumab: is extended VEGF suppression on the horizon?

Ashish Sharma et al. Eye (Lond). 2020 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(Jan):57–65.e5. doi: 10.1016/j.ophtha.2008.10.018. - DOI - PubMed
    1. Mitchell P, Bressler N, Doan QV, Dolan C, Ferreira A, Osborne A, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS One. 2014;9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076243/ - PMC - PubMed
    1. Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye. 2016;30:270–86. doi: 10.1038/eye.2015.217. - DOI - PMC - PubMed
    1. Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23:127–40. doi: 10.1080/13548506.2016.1274040. - DOI - PubMed
    1. Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:914–7. doi: 10.1136/bjophthalmol-2015-306987. - DOI - PubMed

MeSH terms

Substances